Aurinia Pharmaceuticals Inc.

NASDAQ•AUPH

CEO: Mr. Peter S. Greenleaf M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-09-03

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Contact Information

118 Avenue , 14315, Suite 140, Edmonton, AB, T5L 4S6, Canada

250-744-2487

www.auriniapharma.com

Market Cap

$1.90B

P/E (TTM)

6.7

17.5

Dividend Yield

52W High

$16.54

52W Low

$6.83

52W Range

77%

Rank56Top 81.7%

2.5

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$77.11M+0.00%

4-Quarter Trend

EPS

$1.58+0.00%

4-Quarter Trend

FCF

$44.50M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

LUPKYNIS Net Sales Increase Net product sales reached $271.3M USD in 2025, marking a strong 25% increase compared to $216.2M USD reported in 2024.

Operating Cash Flow Surges Cash flows from operating activities were $135.7M USD in 2025, showing a 206% increase from $44.4M USD generated during the prior year.

Net Income Rebounds Strongly Net income for 2025 was $287.2M USD, a substantial positive swing from the $5.752M USD net income recorded in 2024.

Restructuring Costs Decline Restructuring expense dropped significantly to $1.6M USD in 2025, down from $23.1M USD incurred in 2024 following prior year efforts.

Risk Factors

Dependency on LUPKYNIS Success Business success remains substantially dependent on commercializing LUPKYNIS; competition limits potential growth of net product sales.

Patent Litigation Exposure Filed complaints against generic manufacturers alleging patent infringement; litigation costs expected to protect 2037 Patents covering LUPKYNIS.

Reimbursement Policy Uncertainty Commercial prospects for LUPKYNIS may be limited if subject to unfavorable pricing regulations or restrictive third-party coverage policies.

Product Liability Lawsuits Risk Facing potential product liability lawsuits due to severe adverse reactions in LN patients, potentially causing substantial liabilities.

Outlook

Grow LUPKYNIS Product Sales Ability to grow net product sales of LUPKYNIS remains a key forward-looking statement for overall financial performance.

Advance Aritinercept Development Plans include initiating a clinical study for Aritinercept in an additional autoimmune disease during the first half of 2026.

Capital Requirements Uncertainty Future funding needs are uncertain; potential need for additional financing could result in dilution or create operating restrictions.

Maintain Effective Internal Controls Management affirms commitment to maintaining effective internal control over financial reporting as of December 31, 2025.

Peer Comparison

Revenue (TTM)

NVAX

$1.12B

+64.7%

BCRX

$874.84M

+94.1%

HRMY

$868.45M

+21.5%

Gross Margin (Latest Quarter)

SNDX

102.3%

-13.9pp

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EWTX	$3.19B	-18.3	-32.0%	0.7%
VERA	$2.86B	-8.6	-59.7%	10.5%
RCUS	$2.26B	-6.8	-65.8%	8.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

7.3%

Steady Growth

4Q Net Income CAGR

108.2%

Profitability Improved

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:Apr 30, 2026

EPS:$0.20

Revenue:$76.98M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data